share_log

上海医药(601607.SH):I031获得临床试验批准通知书

Shanghai Pharmaceutical (601607.SH): I031 received clinical trial approval notice

Gelonghui Finance ·  May 13 06:01

Gelonghui, May 13 | Shanghai Pharmaceutical (601607.SH) announced that the “I031 tablets” independently developed by the company received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. I031 is a small molecule inhibitor that can inhibit tumor proliferation. Preclinical studies have shown that I031 can inhibit tumor growth in animal models of human tumors. The project was independently developed by Shanghai Pharmaceutical, and the company has full intellectual property rights.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment